Non-HDL cholesterol

Non-HDL cholesterol (non-HDL-C) is simply your total cholesterol minus your HDL. It captures the cholesterol in all the 'bad', artery-clogging lipoproteins: LDL, VLDL, IDL, chylomicron remnants, and Lp(a). Each of those carries apolipoprotein B (ApoB). So non-HDL-C acts as a stand-in for your total ApoB particle count, without needing a direct ApoB test. And unlike calculated LDL-C, it stays reliable even when you have not fasted. It is especially useful if you have high triglycerides, insulin resistance, or type 2 diabetes. In those states, VLDL and remnant particles drive risk but stay invisible to LDL-C. A 2012 JAMA meta-analysis by Boekholdt et al. pooled 8 statin trials (62,154 participants; 38,153 on statins). On-treatment non-HDL-C tracked more closely with heart events than on-treatment LDL-C did. Patients who got LDL-C below 100 mg/dL, but kept non-HDL-C above 130 mg/dL, still had clearly higher residual risk. The 2019 ESC/EAS dyslipidaemia guidelines set non-HDL-C as a secondary target: below 85 mg/dL in very-high-risk patients, and below 100 mg/dL in high-risk ones. Those are 30 mg/dL above the matching LDL-C goals, reflecting the average VLDL cholesterol in the general population. The evidence is observational and from secondary analyses of trials. Mendelian randomization and ApoB genetics support a causal direction. But whether targeting non-HDL-C over LDL-C adds benefit in primary prevention is still open.

Last reviewed: June 22, 2026

This definition is educational and is not medical advice, a diagnosis, or treatment. Talk to a doctor about any health decisions. Read our full medical disclaimer